Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.
Back to dashboard
Company Information
About this company
Key people
Julian C. Baker
Independent Chairman of the Board
Lee Heeson
Executive Vice President - Incyte International
Mohamed Issa
Executive Vice President, Head - U.S. Commercial
Jean-Jacques Bienaime
Independent Director
Otis W. Brawley
Independent Director
Paul J. Clancy
Independent Director
Jacqualyn A. Fouse
Independent Director
Pablo J. Cagnoni
President, Global Head - Research and Development
William J. Meury
Chief Executive Officer, Director
Thomas R. Tray
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
Suketu P. Upadhyay
Chief Financial Officer
Soni Basi
Executive Vice President and Chief Human Resources Officer
Richard Hoffman
Executive Vice President and General Counsel
Matteo Trotta
Executive Vice President, General Manager - Dermatology US
David Gardner
Executive Vice President and Chief Strategy Officer
Click to see more
Key facts
- Shares in issue202.70m
- EPICINCY
- ISINUS45337C1027
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$22.92bn
- Employees2,844
- ExchangeNASDAQ
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.